Shots:

• The EC approval follows CHMP’s positive recommendation for Kixelle to treat DM in adults- adolescents- and children aged ≥1yr. The biosimilar has been approved as a 100 units/ml solution for injection in vial & pre-filled pen presentations
• The EC’s CMA is valid in all EU Member States as well as in the EEA countries including Iceland- Liechtenstein- and Norway
• The approval will allow affordable access to a rapid-acting insulin analog for people with diabetes in the EU

 ­ Ref: Biocon | Image: Business Standard